Background: Controversy exists regarding inhibition of ischemic preconditioning in hyperlipidemic animals. In this study, we tested the hypothesis that hyperlipidemia inhibits the normal reduction of myocardial ischemia on repeated balloon inflations (BIs) during angioplasty. Methods: We studied 33 patients undergoing coronary angioplasty. All underwent a minimum of three BIs. Patients were grouped according to the following plasma cholesterol levels: 13 patients had total cholesterol levels < 200 mg/dL (the normal cholesterol group); and 20 patients had total cholesterol levels > 200 mg/dL (the elevated cholesterol group). Surface ST-segment elevations were recorded at the end of each BI. Results: In the normal cholesterol group, the mean (؎ SD) ST-segment elevation decreased from 0.21 ؎ 0.15 mV during the first BI to 0.11 ؎ 0.11 mV during the third BI (p < 0.05). In the elevated cholesterol group, the respective decrease was from 0.18 ؎ 0.16 to 0.14 ؎ 0.15 mV (p ‫؍‬ not significant) [between-group comparisons: F ‫؍‬ 3.97; p ‫؍‬ 0.02]. The decrease in STsegment elevation was correlated with the total cholesterol levels (r ‫؍‬ ؊0.48; p ‫؍‬ 0.005), the low-density lipoprotein (LDL) cholesterol levels (r ‫؍‬ ؊0.50; p ‫؍‬ 0.003), and the high-density lipoprotein/LDL levels (r ‫؍‬ 0.44; p ‫؍‬ 0.01). Conclusion: Hyperlipidemia prevents the normal reduction of myocardial ischemia on repeated BIs during angioplasty. This leads to the clinical implication that reduction of cholesterol plasma levels, apart from its other known benefits, could also have a beneficial effect on cardioprotection.
S
everal studies [1] [2] [3] [4] [5] [6] have shown that in the course of percutaneous transluminal coronary angioplasty, the severity of myocardial ischemia during balloon inflation (BI) decreases with subsequent inflations, confirming an adaptive response of the myocardium. Regarding the underlying mechanisms of adaptation to ischemia during coronary angioplasty in humans, different studies [2] [3] [4] [5] [6] 7 have suggested the participation of several receptors, such as adenosine, catecholamines, and bradykinin, activate protein kinase C and adenosine triphosphate-dependent K ϩ channels. Experimental studies 8 have demonstrated that atherosclerosis as a result of hyperlipidemia, and in particular hypercholesterolemia per se, is responsible for the loss of preconditioning. However, other experimental data 9, 10 have shown that hypercholesterolemia and atherosclerosis do not abolish protection against myocardial infarction in preconditioned rabbits. Accordingly, the aim of this study was to assess the role of hyperlipidemia in the normal reduction of myocardial ischemia on repeated BIs during angioplasty
Materials and Methods

Patients
The study was approved by the hospital ethics committee, and all patients gave written, informed consent. We studied patients undergoing elective coronary angioplasty for an isolated obstruc- tive lesion in the proximal one third of a coronary artery. All lesions displayed an internal-diameter reduction of 50 to 90%, based on the use of quantitative coronary arteriography. 1 Patients with stenoses of Ͼ 90% were excluded to avoid preinflation ischemia caused by obstruction from the guidewire across the lesion, which would prolong the ischemic time of the first inflation compared with the second. 11 All patients fulfilled the following entry criteria: (1) history of chronic, stable angina pectoris Ն 3 months; and (2) normal left ventricular ejection fraction. Exclusion criteria included unstable angina; medication with sulfonylurea or theophylline, because of their effects on adenosine triphosphate-sensitive potassium channels, which have a known effect on ischemic preconditioning; conduction defects or baseline ST-segment abnormalities on the ECG; history or ECG evidence of previous myocardial infarction; angiographic evidence of collateral circulation; evidence of left ventricular hypertrophy on the ECG; and history of systemic hypertension.
Angioplasty Protocol
All medications, with the exception of aspirin, were discontinued at least 12 h before the procedure. All patients were studied after an overnight fast and did not receive premedication with sedatives. A standard Seldinger technique was used. Heparin, 5,000 IU intra-arterially, was administered as a bolus at the beginning of the procedure and during angioplasty to maintain an activated clotting time of 250 to 300 s.
No other medications were administered until the end of the third BI. After the balloon was positioned across the lesion, three BIs of 120-s duration were performed with the same inflation pressure (Fig 1) . A minimum period of 5 min was allowed for reperfusion between the BIs. Measurements were recorded at the end of the three BIs, just before balloon deflation. After the third BI sequence, the experimental part of the procedure was completed and coronary angioplasty was then concluded in accordance with standard clinical criteria.
Lipid Estimation
The lipid profile for each patient was assessed from a venous blood sample immediately before the angioplasty procedure. Total cholesterol, high-density lipoprotein (HDL), and triglycerides were measured by photometry (Cobas Integra Analyzer; Roche; Basel, Switzerland); low-density lipoprotein (LDL) cholesterol was calculated by Friedwald's formula, because triglyceride levels were Ͻ 400 mg/dL in all patients. Total cholesterol levels Ͻ 200 mg/dL were considered normal; total cholesterol levels Ն 200 mg/dL were considered elevated.
Patients Studied
We studied 33 consecutive patients (Table 1) , 13 patients with normal cholesterol blood levels and 20 patients with elevated cholesterol blood levels. All of the clinical characteristics of the groups with normal and elevated cholesterol were the same, with the exception of the total cholesterol and LDL cholesterol; the triglyceride levels, which were higher in the elevated cholesterol group; and the HDL/LDL, which was lower in the elevated cholesterol group. Sixty-two percent of patients in the normal cholesterol group and 85% of the patients in the elevated cholesterol group had been receiving statin treatment (p ϭ not significant).
Assessment of Myocardial Ischemia
Two surface ECG leads, chosen to reflect likely areas of ischemia during angioplasty, were recorded (Mingograf; Siemens; Solna, Sweden) at a paper speed of 25 mm/s throughout the study. ECG estimations were carried out at the end of 120 s during the first three BIs. Patients without ECG ST-segment elevation during the first BI were excluded from the study.
The ECGs were analyzed by a physician who had no knowledge of the study protocol. ST-segment elevation was measured 80 ms after the J point. The severity of myocardial ischemia was expressed in terms of the ST-segment elevation on the ECG lead with the largest ST shift (expressed in millivolts).
Statistical Analysis
All data were expressed as the mean Ϯ SD. Analysis of variance with repeated measures was used for statistical analysis, followed by Tukey's honest significant difference test for post hoc comparisons. Linear regression analysis, using the least-square differ- Figure 1 . A flowchart detailing the protocol. 
Results
No complications caused by the study protocol were recorded. Heart rate, mean BP, and the double product were unchanged during the three BIs in both groups (Table 2) .
ST-segment shift in the normal cholesterol group decreased by 33% during the second BI and by 48% during the third BI (both p Ͻ 0.05 vs first BI). In the elevated cholesterol group, the ST-segment shift decreased by 17% during the second BI and by 22% during the third BI (both not significant vs first BI)
[ Table 2 , Fig 2] . The decrease of the ST-segment elevation from the first BI to the third BI was correlated with total cholesterol plasma levels (r ϭ Ϫ0.48; p ϭ 0.005), LDL cholesterol levels (r ϭ Ϫ0.50; p ϭ 0.003), and HDL/LDL levels (r ϭ 0.44; p ϭ 0.01). Patients receiving statins had similar response regarding the ST-segment elevation during the three BIs as did the patients not receiving statins.
Discussion
This study demonstrates that hyperlipidemia prevents the normal reduction of myocardial ischemia on repeated BIs. It has been demonstrated that the ST-segment shift accurately reflects the presence of ischemic preconditioning in an experimental study in pigs, 12 whereas the ECG represents a highly sensitive, well-accepted, and simple method for the evaluation of myocardial ischemia during coronary angioplasty in humans. 1, 5, 13 
Hyperlipidemia and Ischemic Preconditioning
Animal studies so far have provided different results concerning whether hypercholesterolemia inhibits ischemic preconditioning. Using ST-segment elevation as an index of protection, Szilvassy et al 8 demonstrated that pacing-induced preconditioning is lost in hypercholesterolemic, atherosclerotic, conscious rabbits. Our own group and others 9, 10 have shown that hypercholesterolemia and atherosclerosis do not abolish protection against myocardial infarction in preconditioned rabbits. The apparently conflicting results of the above-mentioned studies must be interpreted with caution, because in many cases they involve different methodologic approaches and cannot be extrapolated easily to the clinical conditions of coronary angioplasty. Perhaps endothelial dysfunction, which is described well in hyperlipidemia, 14 interferes with preconditioning; however, once total occlusion occurs and the subject progresses to infarction, the effect is less important.
In the present study, we demonstrated that hyperlipidemia prevents the normal reduction of myocardial ischemia on repeated BIs during angioplasty. Hemodynamic variables were not different during the three BIs and were similar in the two studied groups; therefore, the ST-segment changes cannot be attributed to differences in ischemic burden. It could be inferred, however, that the prevention of the reduction of myocardial ischemia in our setting is related to inhibition of ischemic preconditioning.
Because the mechanism of ischemic preconditioning has not been adequately elucidated, it may be quite difficult to clarify the mechanism of the loss of cardioprotection in hyperlipidemic patients. It could be suggested that the formation and release of endogenous protective substances, or the effect of these cardioprotective substances, may be abolished by hyperlipidemia.
Patients with coronary artery disease have atherosclerosis and are in many cases hyperlipidemic. We know that serum cholesterol is inversely related to the increase in coronary blood flow that occurs after rapid atrial pacing in humans. 15 Hyperlipidemia, however, might be associated with less collateral flow, and this would explain the present findings. However, our own data, not shown here, exclude this possibility by demonstrating that hyperlipidemia does not affect collateral flow recruitment during angioplasty.
Hypolipidemic Medications and Preconditioning
Szilvassy et al 8 demonstrated that hypercholesterolemia inhibits preconditioning in rabbits even before the development of any morphologic and functional alterations in vessels. However, clinical trials with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have shown that one of the earliest recognizable benefits after treatment with these drugs is the restoration of endothelium-dependent relaxation. 16 After these results, it was reported that pravastatin restored the infarct size-limiting effect of ischemic preconditioning, blunted by hypercholesterolemia in a rabbit model of myocardial infarction. 17 Taking into account the results of these studies regarding a direct effect of statins on the mechanisms of ischemic preconditioning, and the fact that most of the patients of our study received oral hypolipidemic treatment with a statin, one might hypothesize that our results could be caused by the effect of statin treatment. However, we found no statin-treatment effect on the normal reduction of myocardial ischemia on repeated BIs. The study would have had more power if the patients had been studied when they were not receiving statins, because the latter could influence these results.
Conclusion
Our findings indicate that hyperlipidemia prevents the normal reduction of myocardial ischemia on repeated BIs during angioplasty in humans. This leads to the clinical implication that reduction of cholesterol plasma levels, apart from its other known benefits, could also have a beneficial effect on cardioprotection.
